How a big biotech’s start-up gamble went wrong
Behind the Money
The Importance of Investors Hungering for Returns in Startups
Illumina, the company behind grail's cancer screening technology, is facing a proxy battle. Investors worried that Illumina's ambitious strategy of buying grail had just gone wrong. Behind the Money looks at whether investors hungry for returns will get in the way of a startup's ambitious goals.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
